ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Asciminib has been tested in a phase I trial for patients with BCR-ABL positive CML in chronic and advanced phase and in Ph-positive ALL (ClinicalTrials.gov Identifier: NCT02081378).